Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

← catalyst calendar

NCT05405166 · results posted

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
531actual
Sites
146
Countries
Argentina, Australia, Brazil +18

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2022-06-23actualWhen the study began enrolling
Primary completion2024-11-06actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2027-03-23estimatedThe whole study's end, after follow-up
First posted2022-06-06actualWhen this record first appeared on the registry
Results posted2025-11-14actualWhen the sponsor posted results to the registry
Record updated2025-11-14actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Plasma Cell Myeloma Recurrent

Interventions

  • Drug: Isatuximab IV — also filed as SAR650984, SARCLISA®
  • Drug: Isatuximab SC — also filed as SAR650984
  • Drug: Dexamethasone
  • Drug: Pomalidomide — also filed as Pomalyst or equivalent
  • Drug: Dexamethasone
  • Drug: Montelukast
  • Drug: Paracetamol / Acetaminophen
  • Drug: Diphenhydramine
  • Drug: Methylprednisolone

Primary outcomes

what the primary-completion date above is the date OF
Overall Response Rate (ORR)
measured From first dose of study medication administration (Day 1) up to PCD (06-Nov-2024), approximately 28 months
Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State
measured Pre-dose at Cycle 6 Day 1

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2024-07-10 · 9.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2024-10-24 · 903 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed